Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 13/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3211105 | 0.86 | PPARG (0.67) | PPARGPOLBUSP2SMN1; SMN2 | |
| SCHEMBL3202595 | 0.82 | PPARG (0.72) | PPARGPOLBNPC1USP2SMN1; SMN2 | |
| SCHEMBL3205423 | 0.81 | PPARG (0.62) | PPARGPOLBNPC1 | |
| SCHEMBL5110607 | 0.79 | PPARG (0.74) | PPARG | |
| SCHEMBL3212913 | 0.79 | PPARG (0.70) | PPARGPOLB | |
| SCHEMBL3204724 | 0.79 | PPARG (0.64) | PPARGNPC1USP2SMN1; SMN2 | |
| SCHEMBL3217673 | 0.77 | PPARG (1.00) | PPARG | |
| SCHEMBL3215461 | 0.76 | PPARG (0.67) | PPARGNPC1USP2SMN1; SMN2 | |
| SCHEMBL3215481 | 0.76 | PPARG (0.67) | PPARGNPC1USP2SMN1; SMN2 | |
| SCHEMBL3215661 | 0.76 | PPARG (0.70) | PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100041892-A1 | Therapeutic agent for diabetes | ABE HIDENORI | 2010-02-18 | — | — | US | disclosed |
| US-20090270631-A1 | Therapeutic agent for diabetes | ABE HIDENORI | 2009-10-29 | — | — | US | disclosed |
| US-20080009530-A1 | Therapeutic Agent for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270631-A1 | Therapeutic agent for diabetes | FABP4, SLC5A1, SLC5A2 | PPARG 31/4885POLB 4489/4885NPC1 1683/4885 |
| US-20080009530-A1 | Therapeutic Agent for Diabetes | FABP4, SLC5A1, SLC5A2 | PPARG 30/4885POLB 4616/4885NPC1 1377/4885 |
| US-20100041892-A1 | Therapeutic agent for diabetes | FABP4, SLC5A1, SLC5A2 | PPARG 31/4885POLB 4489/4885NPC1 1683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.